New Oral Therapy Approved for Iron Deficiency in Adults
The FDA has approved Accrufer (ferric maltol; Shield Therapeutics) for the treatment of iron deficiency in adults.
All articles by Diana Ernst, RPh
Darzalex Gets Approval for Additional Multiple Myeloma Indication
The FDA has expanded the approval of Darzalex (daratumumab; Janssen Biotech) to include use in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Novel Reversal Agent for Ticagrelor Gets FDA’s Breakthrough Tx Designation
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to PB2452 (PhaseBio), an investigational reversal agent for ticagrelor.
FDA Approves New Administration Option for Darzalex
The Food and Drug Administration (FDA) has approved a split-dosing regimen for Darzalex (daratumumab; Janssen), which provides clinicians the option of splitting the first infusion of daratumumab over 2 consecutive days.
Next post in Myeloma
